Pune: Serum Institute of India (siiHPV vaccine production had to be postponed for two years due to focus on covidAnd India will start supplying small amounts of the dose to the government in early 2023, a top official has said.
Exports will have to wait till 2024, its chief executive officer Adar Poonawalla He told reporters here on Thursday evening that the company will have to scale up production of more than 15 crores for this.
HPV vaccines prevent some types of cervical cancer.
SII, the world’s largest vaccine manufacturer, went ahead with the production of several COVID vaccines at its facilities located here after the shot was approved for use.
“The HPV facility was used by the COVID vaccines during the pandemic. So we had to delay the big launch until next year,” Poonawalla He said while speaking on the sidelines of a program.
“We will produce in very small quantities and launch with the Indian government in the first quarter of next year. This will be followed by a capacity of 70 million doses which can go up to 150-200 million doses in the subsequent year,” he added.
Poonawalla said the company has already received approval from the Drug Controller General of India for home use of HPV vaccines and added that once the domestic use starts, it expects to get pre-qualification. World Health Organization,
The company has started the paperwork with World Health Organization (WHO), and UNICEF, the vaccine alliance Gavi and is expected to begin exporting to African countries by 2024, by which time it will have ramped up capabilities.
He said that the Indian vaccination program will also give a lot of orders.
“We are just a year behind what we wanted in terms of our capacity,” he said, adding that in 2023, it would start with a capacity of 20 million doses, which would be supplied to the Indian government.
“We used the original HPV vaccine building for Kovovax. So, during the pandemic we had no choice. There were so many other vaccines like dengue and there were so many developments that were postponed for two years,” he said. .
Exports will have to wait till 2024, its chief executive officer Adar Poonawalla He told reporters here on Thursday evening that the company will have to scale up production of more than 15 crores for this.
HPV vaccines prevent some types of cervical cancer.
SII, the world’s largest vaccine manufacturer, went ahead with the production of several COVID vaccines at its facilities located here after the shot was approved for use.
“The HPV facility was used by the COVID vaccines during the pandemic. So we had to delay the big launch until next year,” Poonawalla He said while speaking on the sidelines of a program.
“We will produce in very small quantities and launch with the Indian government in the first quarter of next year. This will be followed by a capacity of 70 million doses which can go up to 150-200 million doses in the subsequent year,” he added.
Poonawalla said the company has already received approval from the Drug Controller General of India for home use of HPV vaccines and added that once the domestic use starts, it expects to get pre-qualification. World Health Organization,
The company has started the paperwork with World Health Organization (WHO), and UNICEF, the vaccine alliance Gavi and is expected to begin exporting to African countries by 2024, by which time it will have ramped up capabilities.
He said that the Indian vaccination program will also give a lot of orders.
“We are just a year behind what we wanted in terms of our capacity,” he said, adding that in 2023, it would start with a capacity of 20 million doses, which would be supplied to the Indian government.
“We used the original HPV vaccine building for Kovovax. So, during the pandemic we had no choice. There were so many other vaccines like dengue and there were so many developments that were postponed for two years,” he said. .